Trials / Unknown
UnknownNCT05310305
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Lei Li · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.
Conditions
- Immune Checkpoint Inhibitors
- Anti-programmed Death-1 Antibody
- Radiotherapy
- Recurrent Cervical Carcinoma
- Metastatic Cervical Carcinoma
- Persistent Advanced Cervical Carcinoma
- Objective Remission Rate
- Progression-free Survival
- Overall Survival
- Severe Adverse Events
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Radiotherapy for targeted lesions and PD-1 antibody | Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy. |
Timeline
- Start date
- 2022-03-26
- Primary completion
- 2022-09-26
- Completion
- 2023-03-26
- First posted
- 2022-04-04
- Last updated
- 2022-04-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05310305. Inclusion in this directory is not an endorsement.